glp 1 and itchy skin An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption Content Warning: This post contains

According to the Summary of Product Characteristics (SmPCs), GLP-1 medications commonly cause nausea (reported in approximately 20-40% of patients with semaglutide and 12-21% with dulaglutide), vomiting, and diarrhoea, particularly during initial treatment and dose escalation

Who is this not for

At a 12 mg maintenance dose, researchers would use 2.4 mL per injection, requiring either larger syringes or split doses

However, the studys multiple groups allotted for only 8 rats per group, meaning the small sample size can cause inaccuracies in data trends

That year one in eight people were thought to be living with obesity around the world (WHO 2024)

Medication-based treatments are emerging, with Zepbound being the first approved drug in this category